US Bancorp
DYN icon

US Bancorp’s Dyne Therapeutics DYN Stock Holding History

US Bancorp’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6K Buy
972
+7
+0.7% +$130 ﹤0.01% 3174
2026
Q1 		$17.5K Buy
965
+565
+141% +$9.74K ﹤0.01% 3169
2025
Q4 		$7.82K Buy
400
+39
+11% +$739 ﹤0.01% 3404
2025
Q3 		$4.57K Buy
361
+19
+6% +$217 ﹤0.01% 3570
2025
Q2 		$3.26K Sell
342
-966
-74% -$10.6K ﹤0.01% 3756
2025
Q1 		$13.7K Sell
1,308
-301
-19% -$4.31K ﹤0.01% 3332
2024
Q4 		$37.9K Buy
1,609
+241
+18% +$7.13K ﹤0.01% 2887
2024
Q3 		$49.1K Buy
1,368
+1,212
+777% +$48.2K ﹤0.01% 2747
2024
Q2 		$5.5K Hold
156
– – ﹤0.01% 3482
2024
Q1 		$4.43K Buy
156
+77
+97% +$1.74K ﹤0.01% 3559
2023
Q4 		$1.05K Buy
79
+18
+30% +$176 ﹤0.01% 3793
2023
Q3 		$547 Hold
61
– – ﹤0.01% 3837
2023
Q2 		$686 Hold
61
– – ﹤0.01% 3849
2023
Q1 		$703 Hold
61
– – ﹤0.01% 3915
2022
Q4 		$707 Hold
61
– – ﹤0.01% 3964
2022
Q3 		$1K Buy
+61
New +$699 ﹤0.01% 3937
2022
Q2 		– Sell
-407
Closed -$4K – 4110
2022
Q1 		$4K Buy
+407
New +$3.46K ﹤0.01% 3663

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

US Bancorp's DYN Position: Q2 2026 in Review

US Bancorp increased its Dyne Therapeutics (DYN) stake by 0.73% in Q2 2026, buying an estimated $130 and bringing the position to 972 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3174.

US Bancorp first reported a position in DYN in Q1 2022 and has held it in 17 quarters since. The position peaked at $49.1K in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • US Bancorp held 972 shares of Dyne Therapeutics worth $21.6K as of Q2 2026.
  • US Bancorp bought 7 Dyne Therapeutics shares in Q2 2026, an estimated $130.
  • Dyne Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3174 holding.
  • US Bancorp first reported a position in Dyne Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • US Bancorp's Dyne Therapeutics position peaked at $49.1K in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.